CCR4 and T-cell non-Hodgkin lymphoma: The generated anti-CCR4 human antibodies demonstrated ADCC-dependent therapeutic anti-tumor effect in vivo in the T-cell deficient nude mice bearing the xenografted human T-cell lymphoma.